Market Closed -
Other stock markets
|
Pre-market 01:41:55 am | |||
6.51 EUR | -0.91% | 6.523 | +0.20% |
May. 21 | Nanobiotix to Transfer Phase 3 Head and Neck Cancer Study Sponsorship | MT |
May. 14 | Nanobiotix to Proceed to Phase 2 Trial of Lung Cancer Treatment | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.96% | 333M | |
+44.48% | 55.07B | |
+43.57% | 40.22B | |
-0.86% | 41.79B | |
-7.59% | 28.17B | |
+12.30% | 26.28B | |
-21.83% | 18.93B | |
+7.15% | 13.03B | |
+29.40% | 12.26B | |
+25.15% | 12.21B |
- Stock Market
- Equities
- NANO Stock
- News Nanobiotix
- Transcript : Nanobiotix S.A., Q4 2023 Earnings Call, Apr 25, 2024